Insite Vision Inc (INSV) 0.3000 $INSV
Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:39AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) was a big mover last session, as its shares rose over7% on the day.
InSite Vision Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 13, 3:05PM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended June 30, 2014. Revenues for the second quarter of 2014 were $6.3 million compared to $19.2 million for the same period in 2013. In the second quarter of 2014, revenues included a $6.0 million payment for the amendment to the Akorn License and royalties for net sales of AzaSite of $0.3 million. In the second quarter of 2013, revenues included $14.5 million for the sale of Besivance royalty rights and royalties for net sales of AzaSite of $4.7 million. Net income for the second quarter of 2014 was $37.1 million, or $0.28 per share, compared to net income of $12.1 million, or $0.09 per share, in the second quarter of 2013. In the second quarter of 2014, InSite recorded a gain of $36.0 million on the extinguishment of the AzaSite Notes.
InSite Vision to Report Second Quarter 2014 Financial Results on August 13, 2014
Business Wire - Tue Aug 05, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the quarter ended June 30, 2014 on Wednesday, August 13, 2014.
InSite Vision awarded broad US patent for bromfenac formulations, with protection through August 2029
M2 - Thu Jul 17, 8:29AM CDT
Ophthalmologic company InSite Vision (Other OTC:INSV) reported on Wednesday the receipt of the US Patent Number 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite from the US Patent and Trademark Office (USPTO).
InSite Vision Announces the Issuance of Broad U.S. Patent Covering Bromfenac Formulations in DuraSite(R)
Business Wire - Wed Jul 16, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent No. 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. The allowed patent contains both composition and method of treatment claims that will broadly cover all of InSite's bromfenac product candidates, including BromSite(TM) (bromfenac 0.075% ophthalmic solution formulated in DuraSite, ISV-303) for the treatment of inflammation and prevention of pain post cataract surgery. Additional bromfenac-containing products in InSite's pipeline covered under this patent include: ISV-101 (bromfenac 0.01%-0.04% ophthalmic solution formulated in DuraSite) for the treatment of dry eye disease, back-of-the eye BromSite indications, such as the prevention of cystoid macular edema (CME), as well as the combination of bromfenac and dexamethasone containing products such as BromDex(TM) (ISV-504). Due to USPTO delays, the patent term was extended by 155 days to provide protection for bromfenac formulations in DuraSite to August 2029.
InSite Vision to Webcast Annual Meeting of Stockholders on July 16, 2014
Business Wire - Tue Jul 15, 3:44PM CDT
InSite Vision Incorporated (OTCBB: INSV) will hold its Annual Meeting of Stockholders at 10:00 a.m. Pacific Time on Wednesday, July 16, 2014 at the company's headquarters at 965 Atlantic Avenue, Alameda, California. Company management will host a live webcast of the meeting, including a corporate presentation, available on the Investor Relations page of the company's website (www.insitevision.com). For those who miss the live broadcast, an archived replay will be available shortly thereafter.
InSite Vision to submit DexaSite's NDA to US FDA for blepharitis in adults in 2015
M2 - Wed Jul 09, 5:48AM CDT
Ophthalmic company InSite Vision (Other OTC:INSV) disclosed on Tuesday that it plans to submit a New Drug Application (NDA) for DexaSite (dexamethasone 0.1% in DuraSite) for the treatment of blepharitis in adults in 2015, following completion of remaining chemistry and manufacturing work and the meeting with the US Food and Drug Administration (FDA).
InSite Vision Plans to Submit New Drug Application to FDA for DexaSite(TM) for the Treatment of Blepharitis in Adults
Business Wire - Tue Jul 08, 7:30AM CDT
--European post-Phase 3/pre-MAA DexaSite and AzaSite Plus Blepharitis Discussions Scheduled for Q3 2014
InSite Vision Announces Agreement With Noteholders to Extinguish Debt in Exchange for One-Time Payment
Business Wire - Thu Jun 12, 7:30AM CDT
--InSite Will Now Directly Receive Tiered Royalties from Sales of AzaSite; Secured 16% Notes and Accrued Interest Liabilities Totaling $43.9 Cancelled
InSite Vision Reports Fourth Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 27, 12:00PM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter and year ended December 31, 2013. Revenues for the year ended December 31, 2013 were $30.8 million compared to $21.6 million for the same period in 2012. Net income for the year ended December 31, 2013 was $5.8 million, or $0.04 per share, compared to a net loss of $8.3 million, or $0.06 per share, in 2012. Revenues for the fourth quarter of 2013 were $1.1 million compared to $5.4 million for the same period in 2012. Net loss for the fourth quarter of 2013 was $5.0 million, or $0.04 per share, compared to a net loss of $1.8 million, or $0.01 per share, in the fourth quarter 2012. As of December 31, 2013, cash, cash equivalents and short-term investments totaled $8.3 million.
InSite Vision to Report Fourth Quarter and Year-End 2013 Financial Results on March 27, 2014
Business Wire - Fri Mar 21, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the fourth quarter and year-ended December 31, 2013 on Thursday, March 27, 2014.
InSite Vision receives USD1m in royalties from the sale of Besivance
M2 - Wed Feb 05, 4:47AM CST
US-based ophthalmologic company InSite Vision Incorporated (Other OTC:INSV) stated on Tuesday that Besivance 2013 net sales has generated an additional USD1m milestone payment.
InSite Vision Announces Achievement of the $1 Million Milestone From the Sale of Besivance(R) Royalty
Business Wire - Tue Feb 04, 7:30AM CST
InSite Vision Incorporated (OTCBB: INSV) today announced that Besivance 2013 net sales achieved the levels necessary to earn InSite Vision an additional $1 million milestone payment from the Besivance royalty purchasers, SWK Funding LLC, a wholly-owned subsidiary of SWK Holdings Corporation (OTCBB: SWKH), and Bess Royalty, L.P. The $16 million total cash consideration to InSite Vision included a $15 million upfront payment in April, 2013, and a $1 million milestone payment which will be paid this month. Besivance (besifloxacin ophthalmic suspension) 0.6% is marketed globally by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, for the treatment of bacterial conjunctivitis.
Bacterial Conjunctivitis - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Bacterial Conjunctivitis
M2 - Wed Jan 22, 5:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/s6nmg2/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Bacterial Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. Bacterial Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Cellceutix Corporation -China Grand Wuhan General Pharmaceutical Research Institute -Daiichi Sankyo Company, Limited -EyeGate Pharmaceuticals, Inc. -InSite Vision Incorporated -NovaBay Pharmaceuticals, Inc. -Ocular Therapeutix, Inc. For more information visit http://www.researchandmarkets.com/research/s6nmg2/bacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - InSite Vision (OTCQB: INSV)
WorldStockWire - Fri Sep 06, 11:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
InSite Vision Announces Patent Issuance on DuraSite(R) 2 Ophthalmic Drug Delivery System
Business Wire - Thu Aug 15, 3:30PM CDT
InSite Vision Incorporated (OTCBB: INSV) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,501,800 on the Company's DuraSite(R) 2next-generation enhanced drug delivery system. DuraSite 2 provides a broad platform for developing topically delivered ocular drugs with enhanced tissue penetration in order to improve efficacy and dosing convenience. This patent will provide utility/composition of matter protection to 2029 for both the delivery system and the drugs that are formulated with DuraSite 2.
InSite Vision to Report Second Quarter 2013 Financial Results on August 8, 2013
Business Wire - Thu Jul 25, 7:30AM CDT
InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the second quarter ended June 30, 2013 on Thursday, August 8, 2013.
InSite Vision Announces Top-line Results from the DOUBle Phase 3 Clinical Study for the Treatment of Moderate-to-Severe Blepharitis
Business Wire - Tue Jul 23, 3:05PM CDT
--AzaSite Plus and DexaSite Demonstrated Statistically Significant Improvements in Clinical Signs and Symptoms at Day 15
Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:39AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) was a big mover last session, as its shares rose over7% on the day.
InSite Vision Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 13, 3:05PM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended June 30, 2014. Revenues for the second quarter of 2014 were $6.3 million compared to $19.2 million for the same period in 2013. In the second quarter of 2014, revenues included a $6.0 million payment for the amendment to the Akorn License and royalties for net sales of AzaSite of $0.3 million. In the second quarter of 2013, revenues included $14.5 million for the sale of Besivance royalty rights and royalties for net sales of AzaSite of $4.7 million. Net income for the second quarter of 2014 was $37.1 million, or $0.28 per share, compared to net income of $12.1 million, or $0.09 per share, in the second quarter of 2013. In the second quarter of 2014, InSite recorded a gain of $36.0 million on the extinguishment of the AzaSite Notes.
InSite Vision to Report Second Quarter 2014 Financial Results on August 13, 2014
Business Wire - Tue Aug 05, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the quarter ended June 30, 2014 on Wednesday, August 13, 2014.
InSite Vision awarded broad US patent for bromfenac formulations, with protection through August 2029
M2 - Thu Jul 17, 8:29AM CDT
Ophthalmologic company InSite Vision (Other OTC:INSV) reported on Wednesday the receipt of the US Patent Number 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite from the US Patent and Trademark Office (USPTO).
InSite Vision Announces the Issuance of Broad U.S. Patent Covering Bromfenac Formulations in DuraSite(R)
Business Wire - Wed Jul 16, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent No. 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. The allowed patent contains both composition and method of treatment claims that will broadly cover all of InSite's bromfenac product candidates, including BromSite(TM) (bromfenac 0.075% ophthalmic solution formulated in DuraSite, ISV-303) for the treatment of inflammation and prevention of pain post cataract surgery. Additional bromfenac-containing products in InSite's pipeline covered under this patent include: ISV-101 (bromfenac 0.01%-0.04% ophthalmic solution formulated in DuraSite) for the treatment of dry eye disease, back-of-the eye BromSite indications, such as the prevention of cystoid macular edema (CME), as well as the combination of bromfenac and dexamethasone containing products such as BromDex(TM) (ISV-504). Due to USPTO delays, the patent term was extended by 155 days to provide protection for bromfenac formulations in DuraSite to August 2029.
InSite Vision to Webcast Annual Meeting of Stockholders on July 16, 2014
Business Wire - Tue Jul 15, 3:44PM CDT
InSite Vision Incorporated (OTCBB: INSV) will hold its Annual Meeting of Stockholders at 10:00 a.m. Pacific Time on Wednesday, July 16, 2014 at the company's headquarters at 965 Atlantic Avenue, Alameda, California. Company management will host a live webcast of the meeting, including a corporate presentation, available on the Investor Relations page of the company's website (www.insitevision.com). For those who miss the live broadcast, an archived replay will be available shortly thereafter.
InSite Vision to submit DexaSite's NDA to US FDA for blepharitis in adults in 2015
M2 - Wed Jul 09, 5:48AM CDT
Ophthalmic company InSite Vision (Other OTC:INSV) disclosed on Tuesday that it plans to submit a New Drug Application (NDA) for DexaSite (dexamethasone 0.1% in DuraSite) for the treatment of blepharitis in adults in 2015, following completion of remaining chemistry and manufacturing work and the meeting with the US Food and Drug Administration (FDA).
InSite Vision Plans to Submit New Drug Application to FDA for DexaSite(TM) for the Treatment of Blepharitis in Adults
Business Wire - Tue Jul 08, 7:30AM CDT
--European post-Phase 3/pre-MAA DexaSite and AzaSite Plus Blepharitis Discussions Scheduled for Q3 2014
InSite Vision Announces Agreement With Noteholders to Extinguish Debt in Exchange for One-Time Payment
Business Wire - Thu Jun 12, 7:30AM CDT
--InSite Will Now Directly Receive Tiered Royalties from Sales of AzaSite; Secured 16% Notes and Accrued Interest Liabilities Totaling $43.9 Cancelled
InSite Vision Reports Fourth Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 27, 12:00PM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter and year ended December 31, 2013. Revenues for the year ended December 31, 2013 were $30.8 million compared to $21.6 million for the same period in 2012. Net income for the year ended December 31, 2013 was $5.8 million, or $0.04 per share, compared to a net loss of $8.3 million, or $0.06 per share, in 2012. Revenues for the fourth quarter of 2013 were $1.1 million compared to $5.4 million for the same period in 2012. Net loss for the fourth quarter of 2013 was $5.0 million, or $0.04 per share, compared to a net loss of $1.8 million, or $0.01 per share, in the fourth quarter 2012. As of December 31, 2013, cash, cash equivalents and short-term investments totaled $8.3 million.
InSite Vision to Report Fourth Quarter and Year-End 2013 Financial Results on March 27, 2014
Business Wire - Fri Mar 21, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the fourth quarter and year-ended December 31, 2013 on Thursday, March 27, 2014.
InSite Vision receives USD1m in royalties from the sale of Besivance
M2 - Wed Feb 05, 4:47AM CST
US-based ophthalmologic company InSite Vision Incorporated (Other OTC:INSV) stated on Tuesday that Besivance 2013 net sales has generated an additional USD1m milestone payment.
InSite Vision Announces Achievement of the $1 Million Milestone From the Sale of Besivance(R) Royalty
Business Wire - Tue Feb 04, 7:30AM CST
InSite Vision Incorporated (OTCBB: INSV) today announced that Besivance 2013 net sales achieved the levels necessary to earn InSite Vision an additional $1 million milestone payment from the Besivance royalty purchasers, SWK Funding LLC, a wholly-owned subsidiary of SWK Holdings Corporation (OTCBB: SWKH), and Bess Royalty, L.P. The $16 million total cash consideration to InSite Vision included a $15 million upfront payment in April, 2013, and a $1 million milestone payment which will be paid this month. Besivance (besifloxacin ophthalmic suspension) 0.6% is marketed globally by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, for the treatment of bacterial conjunctivitis.
Bacterial Conjunctivitis - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Bacterial Conjunctivitis
M2 - Wed Jan 22, 5:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/s6nmg2/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Bacterial Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. Bacterial Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Cellceutix Corporation -China Grand Wuhan General Pharmaceutical Research Institute -Daiichi Sankyo Company, Limited -EyeGate Pharmaceuticals, Inc. -InSite Vision Incorporated -NovaBay Pharmaceuticals, Inc. -Ocular Therapeutix, Inc. For more information visit http://www.researchandmarkets.com/research/s6nmg2/bacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - InSite Vision (OTCQB: INSV)
WorldStockWire - Fri Sep 06, 11:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
InSite Vision Announces Patent Issuance on DuraSite(R) 2 Ophthalmic Drug Delivery System
Business Wire - Thu Aug 15, 3:30PM CDT
InSite Vision Incorporated (OTCBB: INSV) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,501,800 on the Company's DuraSite(R) 2next-generation enhanced drug delivery system. DuraSite 2 provides a broad platform for developing topically delivered ocular drugs with enhanced tissue penetration in order to improve efficacy and dosing convenience. This patent will provide utility/composition of matter protection to 2029 for both the delivery system and the drugs that are formulated with DuraSite 2.
InSite Vision to Report Second Quarter 2013 Financial Results on August 8, 2013
Business Wire - Thu Jul 25, 7:30AM CDT
InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the second quarter ended June 30, 2013 on Thursday, August 8, 2013.
InSite Vision Announces Top-line Results from the DOUBle Phase 3 Clinical Study for the Treatment of Moderate-to-Severe Blepharitis
Business Wire - Tue Jul 23, 3:05PM CDT
--AzaSite Plus and DexaSite Demonstrated Statistically Significant Improvements in Clinical Signs and Symptoms at Day 15
